1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). This program supports small molecule drug discovery and development for disorders of the nervous system, which can include AD/ADRD.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute on Aging (NIA), National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | Office of the Vice Chancellor for Research and Innovation (OVCRI) Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) Funding & Proposal Support Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) Direct Link to Opportunity https://grants.
nih. gov/grants/guide/pa-files/PAR-25-051. html National Institutes of Health June 15, 2025 Deadline is for Letters of Intent July 15, 2025 is the Full Application Deadline
According to the current listing, eligibility includes: Not explicitly detailed in the snippet. Generally, NIH programs are open to universities and research institutions. Confirm the full requirements in the official notice before applying.
The published deadline was August 19, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is funded by National Institute on Aging (NIA), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Technology Transfer (STTR) Program is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA STTR program encourages small businesses to collaborate formally with research institutions to develop and commercialize innovative treatments or technologies to help people enjoy healthier lives as they age, including solutions for Alzheimer's disease and related dementias. This program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.
Small Business Innovation Research (SBIR) Program is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA SBIR program funds small businesses to develop and validate technologies that enhance the health and well-being of older adults, with high interest in technologies addressing unmet needs, improving care delivery, or reducing caregiver burden. This includes AI/ML methods for early detection and monitoring, assistive devices, robotics, sensors, and digital health products.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The NIH Extramural Loan Repayment Program pays up to $50,000 a year against educational debt at roughly a 50% success rate — better odds than almost any NIH research grant. For FY2027 the six extramural subcategories collapse into three: L30, L40, and L70. Applicants who would have used L32, L50, or L60 must now pick a new lane. Here is the crosswalk, the 20% debt-to-salary rule, and why the consolidation changes how you frame the research.
Read articleNOT-OD-26-098 bars K award funds from supporting clinical trials, feasibility studies, and ancillary studies for due dates on or after October 12, 2027, and retires the Independent Clinical Trial Required K NOFOs. NIH has no replacement mechanism yet — only an RFI closing September 30, 2026. Here is what the policy actually says, who it hits, and how to sequence around it.
Read articleNIH proposed on August 14 to withhold overall impact scores and percentiles from applicants, replacing them with three bands: Most competitive, Competitive, Not discussed. Paylines already vanished in January. Here is what applicants actually lose, what survives in the summary statement, and how to rebuild a resubmission decision rule without a number.
Read article